MIR181A1HG

Across TCGA pan-cancer cohorts, MIR181A1HG RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MIR181A1HG’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MIR181A1HG RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR181A1HG is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

BLCA, BRCA, and STAD are the cancer types where MIR181A1HG tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR181A1HG RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	All	+0.105	.007	7	view →
BRCA	Female	All	+0.173	.006	6	view →
STAD	Male	All	+0.078	<.001	6	view →
KICH	Male	All	−0.055	<.001	5	view →
HNSC	Female	III,IV	+0.032	.001	5	view →
COAD	All	All	+0.025	.027	5	view →
LUSC	Male	III,IV	−0.090	.011	3	view →
KIRC	All	All	+0.024	.005	3	view →
UCEC	All	All	+0.068	.035	2	view →
LUAD	All	All	+0.269	.047	1	view →
ESCA	All	All	+0.090	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MIR181A1HG–BLCA

Open the BLCA breakdown →